Kailera snags Lilly’s Zepbound brand leader

28 January 2025

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman (pictured, above) as chief commercial officer (CCO).

In this role, Ms Coleman will be responsible for establishing and executing Kailera’s overall commercial strategy for the company’s advanced clinical-stage product candidates for the treatment of obesity and related conditions.

She joins Kailera—which only announced its launch in October with a $400 million Series A financing, having acquired rights to four metabolic disease assets outside of greater China from Jiangsu Hengrui Pharmaceuticals (SHA: 600276) earlier in the year—from Eli Lilly.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK